Drugs

PEER-REVIEWED FEATURE

Nivolumab Plus Relatlimab: Adis Evaluation

Key Points

- A fixed-dose combination of nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 blocking antibody) is being developed by Bristol Myers Squibb for the treatment of advanced cancer
- Received its first approval on 18 March 2022 in the USA
- Approved for use in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg with unresectable or metastatic melanoma

Summary

Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag™) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers.

Both drugs are immunoglobulin G4 (IgG4) monoclonal antibodies developed to target immune checkpoints, with nivolumab targeting the programmed cell death protein 1 (PD-1) receptor and relatlimab being a newly developed, first-in-class drug targeting the lymphocyte-activation gene 3 (LAG-3) protein.

In March 2022, nivolumab plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and paediatric patients aged ≥ 12 years who weigh ≥ 40 kg.